Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

6 Oct 2009 07:00

RNS Number : 2761A
Byotrol PLC
06 October 2009
 



Byotrol plc (the "Company")

UPDATE ON TRADING

The Board is pleased to announce a further positive update on trading in relation to the six months ended 30 September 2009.

As highlighted in the announcement dated 17 September, the first half of the current financial year has been characterised by a significant increase in orders for Byotrol products. This trend has continued through to the end of the half year and as a result the Board is pleased to report that product sales for the six months ended 30 September 2009 will be in the order of £1.5m (£0.2m for the comparative period). There was an additional one off license payment of £450k bringing total revenues to approximately £1.9m as compared to £0.4m for the same period last year.

The Board believes certain key factors have underpinned the interest in, and orders for, Byotrol products. One has been the increased public and businesss awareness of the products following the success of the Manchester Royal Infirmary trial which demonstrated that Byotrol outperformed the NHS's gold standard cleaning regime. Another is the increased public awareness of the requirement for better personal hygiene stemming, in part, from the threat of swine flu. The third key factor is the continued growth in the recognition of Byotrol's superiority to other products in that it continues to work even when dry.

Highlights of the Company's activities during the period include the receipt of significant orders for supply to major retailers for the protection of their staff. The Company has also despatched material orders to Arco, one of the UK's leading Health and Safety product suppliers. 

"I am very pleased with the sales performance for the first half" said CEO David McRobbie. "The unprecedented increase in orders gave rise to some temporary issues in relation to sourcing bottles and caps and the Company turned to suppliers in both Europe and North America. This has had an unavoidable short term impact on margins. We have, however, addressed the bottles supply issue via a manufacturing arrangement with a major bottle supplier. Accordingly, the Board expect that margins should improve in the second half of the current financial year."

The eight fold increase in activity levels has also been reflected in an increased working capital requirement and the Board has taken steps to address this. As at 30 September, the Company had cash of £1.6m.

The Company has a good forward order book for the third quarter of the financial year but the nature of the business means that, at the current time, there is more limited visibility for the final quarter. As a consequence, the Board's current view is that the results for the financial year will be in line with market expectations.

The Board will provide a further update at the time of the announcement of the interim results in mid November.

Enquiries:

 

Byotrol plc
 
 
Richard Bell, Finance Director
 
Tel 0161 277 9518
Charles Stanley Securities
Nominated Adviser & Broker
 
 
Philip Davies / Carl Holmes
Tel 020 7149 6000

 

6 October 2009 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUUGAGUUPBPUA
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.